Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women

Details

• Alternative Title:
  Open AIDS J
• Personal Author:
  Ratanasuwan, Winai ; Jariyasethpong, Tavatchai ; Anekthananon, Thanomsak ; Intalapaporn, Poj ; Kongpatanakul, Supornchai ; Pongnarin, Piyapat ; Wasinrapee, Punneeporn ; Chantharojwong, Nartlada ; Raengsakulrach, Boonyos ; Peters, Philip J ; McNicholl, Janet ; McConnell, Michelle S ; Weidle, Paul J
• Description:
  Background:
  
  We performed a nested case-control study of Thai women prescribed nevirapine-based antiretroviral therapy (ART) to determine if development of rash or hepatotoxicity during the first 24 weeks of treatment is associated with plasma nevirapine concentrations.
  
  Method:
  
  From May 2005-January 2007, we enrolled 217 women initiating nevirapine-based ART in Thailand. Cases (n = 54) were women who during the first 24 weeks of treatment with nevirapine developed rash (any grade, n = 42) or hepatotoxicity (≥grade 2, n = 22, [10 had both]). Controls were the next enrolled woman who was confirmed not to meet the case definition during the first 24 weeks. Nevirapine concentrations after the two week lead-in dose of 200 mg once daily were compared between cases and controls by Wilcoxon rank-sum tests.
  
  Results:
  
  We found no difference in Week 2 pre-dose nevirapine concentrations: cases median = 3,528 ng/mL (n = 24), controls median = 3,150ng/mL (n = 30), p = 0.5. Cases had higher post-dose nevirapine concentrations (median = 6,150 ng/mL, n = 21) than controls (median = 4,746 ng/mL, n = 20, p = 0.02). When limited to cases who developed a rash at Week 2, we found no differences in the pre-dose (median = 3,270 ng/mL, n = 12, p = 0.9) or post-dose nevirapine concentration (median = 5,443 ng/mL, n = 9, p = 0.4) compared with controls.
  
  Conclusions:
  
  We cannot conclude definitively that nevirapine concentrations at two weeks of therapy are associated with rash or hepatotoxicity. It is unlikely that therapeutic drug monitoring at that time will improve identification of patients at risk for rash or hepatotoxicity.
  
  
• Subjects:
  Adverse Effect Antiretroviral Article Hepatotoxicity Nevirapine Rash Thailand.
• Source:
  Open AIDS J. 2012; 6:266-273.
• Pubmed ID:
  23304252
• Pubmed Central ID:
  PMC3537114
• Document Type:
  Journal Article
• Volume:
  6
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:46735be96c6d62f4c474e545035cf957c1371f2dfb681fd2a39527243cc94e67
• Download URL:
  https://stacks.cdc.gov/view/cdc/43363/cdc_43363_DS1.pdf
• File Type:
  [PDF - 1.25 MB ]